首页> Urologic oncology> Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.

Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sanjana,Ranganathan

第一单位： Department of Urology, Houston Methodist Hospital, Houston, TX.

作者： Sanjana,Ranganathan ^[1] ; Carlos,Riveros ^[1] ; Jiaqiong,Xu ^[2] ; Siqi,Hu ^[1] ; Michael,Geng ^[3] ; Emily,Huang ^[1] ; Zachary,Melchiode ^[1] ; Jun,Zhang ^[4] ; Eleni,Efstathiou ^[4] ; Keith Syson,Chan ^[5] ; Christopher J D,Wallis ^[6] ; Guru,Sonpavde ^[7] ; Raj,Satkunasivam ^[8]

作者单位： Department of Urology, Houston Methodist Hospital, Houston, TX. ^[1] Center for Health Data Science and Analytics, Houston Methodist Hospital, Houston, TX. ^[2] Department of Urology, Houston Methodist Hospital, Houston, TX; School of Engineering Medicine, Texas A&M University, Houston, TX. ^[3] Department of Medical Oncology, Houston Methodist Hospital, Houston, TX. ^[4] Center for TME Spatial Profiling in GU Oncology, Houston Methodist Research Institute, Houston, TX. ^[5] Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada; Division of Urology, University of Toronto, Toronto, Ontario, Canada; Division of Urology, Mount Sinai Hospital, Toronto, Ontario, Canada. ^[6] AdventHealth Cancer Institute, Orlando, FL. ^[7] Department of Urology, Houston Methodist Hospital, Houston, TX. Electronic address: raj.satkunasivam@gmail.com. ^[8]

关键词 Chemoimmunotherapy Immunotherapy Overall survival Urologic oncology Urothelial carcinoma